- Home
- HLVX vs SLS Comparison
HLVX vs SLS Comparison
Compare HLVX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- SLS
- Stock Information
- Founded
- HLVX 2020
- SLS 2012
- Country
- HLVX United States
- SLS United States
- Employees
- HLVX N/A
- SLS N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- SLS Health Care
- Exchange
- HLVX Nasdaq
- SLS Nasdaq
- Market Cap
- HLVX 83.7M
- SLS 89.6M
- IPO Year
- HLVX 2022
- SLS N/A
- Fundamental
- Price
- HLVX $1.39
- SLS $1.09
- Analyst Decision
- HLVX Hold
- SLS
- Analyst Count
- HLVX 5
- SLS 0
- Target Price
- HLVX $2.33
- SLS N/A
- AVG Volume (30 Days)
- HLVX 144.6K
- SLS 815.8K
- Earning Date
- HLVX 03-28-2025
- SLS 03-20-2025
- Dividend Yield
- HLVX N/A
- SLS N/A
- EPS Growth
- HLVX N/A
- SLS N/A
- EPS
- HLVX N/A
- SLS N/A
- Revenue
- HLVX N/A
- SLS N/A
- Revenue This Year
- HLVX N/A
- SLS N/A
- Revenue Next Year
- HLVX N/A
- SLS N/A
- P/E Ratio
- HLVX N/A
- SLS N/A
- Revenue Growth
- HLVX N/A
- SLS N/A
- 52 Week Low
- HLVX $1.37
- SLS $0.77
- 52 Week High
- HLVX $16.31
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- HLVX 20.06
- SLS 38.41
- Support Level
- HLVX $1.41
- SLS $1.13
- Resistance Level
- HLVX $1.71
- SLS $1.25
- Average True Range (ATR)
- HLVX 0.07
- SLS 0.07
- MACD
- HLVX -0.03
- SLS -0.01
- Stochastic Oscillator
- HLVX 7.50
- SLS 8.74
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.